Skip to content
    Real-World Studies

    Real-World First-Line mHSPC Treatment Trends

    Raval et alThe Oncologist

    A cross-sectional study evaluated real-world first-line treatment patterns for 23,101 men with metastatic hormone-sensitive prostate cancer (mHSPC) treated between 2020 and 2024 across EU4 (n = 15,275), the UK (n = 4,875), and Asia (Japan and China; n = 2,951) using the IQVIA Oncology Dynamics database. Overall initial treatment selection varied markedly by geography. Across the study period, ADT monotherapy accounted for 29% to 44% of initial regimens in EU4 and the UK compared with 50% to 59% in Asia. Conversely, doublet therapy with ADT plus an androgen receptor pathway inhibitor (ARPI) was utilized in 47% of patients in EU4, 54% in the UK, and 35% to 38% in Asia. Patients presenting with de novo mHSPC received combination therapy at higher rates than those with recurrent mHSPC. Longitudinal analysis demonstrated a clear transition toward combination regimens from 2020 to 2024. ADT monotherapy decreased from 60% to 24% in EU4, from 54% to 23% in the UK, and from 83% to 39% in Asia, offset by corresponding gains in ADT plus ARPI use. Concurrently, triplet therapy comprising ADT, an ARPI, and docetaxel expanded from 0.1% in 2020 to 10% in 2024, gaining notable traction in EU4 and the UK starting in 2023, while uptake lagged in Asia. Despite these shifts toward treatment intensification, one in four patients globally continued to receive ADT monotherapy as of 2024.

    Key Takeaways

    • Between 2020 and 2024, first-line ADT monotherapy fell from 60% to 24% in EU4, 54% to 23% in the UK, and 83% to 39% in Asia, driven by rising adoption of ADT plus ARPI doublet regimens.
    • Triplet therapy with ADT, an ARPI, and docetaxel expanded from 0.1% in 2020 to 10% in 2024 across the cohort, with prominent uptake emerging in 2023 in Europe and the UK alongside slower uptake in Asia.
    • Despite broad shifts toward treatment intensification—particularly in de novo versus recurrent mHSPC—approximately one-fourth of patients still received ADT monotherapy in 2024.